{"slug":"semaglutide-cognition","verification":{"valid":true,"entries":2,"head":"096cd56ae00b47bdbb526f17c36918d110370a42b38aabd291b4d9f916f6041d"},"energy":{"passes":2,"tokens_in":34028,"tokens_out":3263,"tokens_total":37291,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"096cd56ae00b47bdbb526f17c36918d110370a42b38aabd291b4d9f916f6041d"},"provenance":[{"ts":"2026-06-30T00:30:07.890Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semaglutide for Cognition\nSlug: semaglutide-cognition\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-com","response":"{\n  \"slug\": \"semaglutide-cognition\",\n  \"title\": \"Semaglutide for Cognition: Evidence-Graded Look at Metabolic and Brain Pathways\",\n  \"body\": \"## What's breaking down\\n\\nCognitive function depends on steady brain energy use, controlled inflammation, and ongoing repair of neural connections. When metabolic stress rises—such as poor glucose handling or excess body weight—repair pathways can lag behind daily wear. This imbalance shows up as slower thinking, memory slips, or faster decline in conditions like mild cognitive impairment. Semaglutide research focuses on upstream metabolic shifts rather than direct symptom masking.\\n\\n## Why Semaglutide might help you\\n\\n1. What keeps failing: Brain cells face metabolic strain when blood sugar and insulin signaling drift; inflammation can then outrun local repair.\\n2. What Semaglutide is studied to do: GLP-1 receptor activation is examined for improving whole-body metabolic control and downstream effects on brain glucose use and inflammatory signals.\\n3. Therefore for you: If metabolic load contributes to your cognitive picture, the compound is discussed for targeting those repair-support layers, not for covering up day-to-day fog.\\n\\n## How these fit together\\n\\nSingle-compound focus. Semaglutide maps to metabolic load and body-weight effects that may indirectly support brain energy balance. No sibling peptides in scope here.\\n\\n## What the evidence actually shows\\n\\nHuman observational data link semaglutide use in type 2 diabetes to lower first-time Alzheimer's diagnoses versus other diabetes drugs. One target-trial emulation of over one million patients found hazard ratios between 0.33 and 0.59 (human, real-world).\\n\\nPhase 3 EVOKE and EVOKE+ trials in early symptomatic Alzheimer's showed no slowing of cognitive or functional decline over three years (human, randomized, negative primary outcome).\\n\\nA 12-month matched cohort study of more than 20,000 patients per arm found semaglutide associated with reduced risk of cognit","tokens_in":34028,"tokens_out":3263,"cost":0,"prev":"genesis","hash":"dfad2180abb3e15f9773113a187e5e2588b14aeb81192280966968c49d703375"},{"ts":"2026-07-17T02:41:44.289Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-cognition","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dfad2180abb3e15f9773113a187e5e2588b14aeb81192280966968c49d703375","hash":"096cd56ae00b47bdbb526f17c36918d110370a42b38aabd291b4d9f916f6041d"}]}